Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.7468
+0.0466 (6.66%)
At close: May 12, 2025, 4:00 PM
0.3900
-0.3568 (-47.78%)
After-hours: May 12, 2025, 7:59 PM EDT
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$315,847
Profits / Employee
-$535,197
Market Cap
167.81M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SGMO News
- 2 hours ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - Business Wire
- 2 hours ago - Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Business Wire
- 4 hours ago - Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - Business Wire
- 6 days ago - Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Business Wire
- 6 days ago - Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - Business Wire
- 14 days ago - Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire
- 5 weeks ago - Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal - Seeking Alpha
- 5 weeks ago - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire